Collaborations & Alliances

TWi Biotech Forms Agreement with Castle Creek Pharma

To advance its drug candidate AC-203 for epidermolysis bullosa

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

TWi Biotechnology, and Castle Creek Pharmaceuticals (CCP) have entered into a development and commercialization agreement for its lead drug candidate AC-203, which is currently in development for the treatment of epidermolysis bullosa (EB). TWiB grants to CCP an exclusive license of AC-203, covering a worldwide territory with the exception of Asia but including Australia and New Zealand, to develop, register and commercialize AC-203. TWiB is eligible to receive an upfront payment and milestone p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters